Real-World Eligibility of Diabetic Macular Edema Patients for Anti-VEGF Trials: Implications for Clinical Practice and Health Equity
Posted inDiabetes & Endocrinology news Ophthalmology

Real-World Eligibility of Diabetic Macular Edema Patients for Anti-VEGF Trials: Implications for Clinical Practice and Health Equity

A significant proportion of real-world diabetic macular edema patients are excluded from clinical trials of anti-VEGF therapy due to stringent systemic criteria, disproportionately affecting racial minorities. This study highlights the need for broader inclusion to enhance trial applicability.
FAc Intravitreal Implant Achieves Comparable Visual Outcomes with 53% Fewer Injections in Diabetic Macular Edema: Phase 4 NEW DAY Study
Posted innews Ophthalmology

FAc Intravitreal Implant Achieves Comparable Visual Outcomes with 53% Fewer Injections in Diabetic Macular Edema: Phase 4 NEW DAY Study

The Phase 4 NEW DAY study demonstrates that fluocinolone acetonide (FAc) 0.19 mg implant as baseline therapy achieves similar visual acuity and anatomical improvements compared to aflibercept in diabetic macular edema patients, while significantly reducing total injection burden despite not meeting the primary rescue injection endpoint.